JP2005507901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005507901A5 JP2005507901A5 JP2003532498A JP2003532498A JP2005507901A5 JP 2005507901 A5 JP2005507901 A5 JP 2005507901A5 JP 2003532498 A JP2003532498 A JP 2003532498A JP 2003532498 A JP2003532498 A JP 2003532498A JP 2005507901 A5 JP2005507901 A5 JP 2005507901A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- medicament
- compound
- stroke
- skull
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical group C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- -1 benzyl (2R) -3,4-dihydro-2H-chromen-2-ylmethyl Chemical group 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- UPBWIICFGYMCPC-UHFFFAOYSA-N bis(2-methoxyethoxy)aluminum Chemical compound COCCO[Al]OCCOC UPBWIICFGYMCPC-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009297 electrocoagulation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- BHAGEKGIBBDSFZ-UHFFFAOYSA-N n-benzyl-4-[tert-butyl(dimethyl)silyl]oxy-3,4-dihydro-2h-chromene-2-carboxamide Chemical compound O1C2=CC=CC=C2C(O[Si](C)(C)C(C)(C)C)CC1C(=O)NCC1=CC=CC=C1 BHAGEKGIBBDSFZ-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10148425A DE10148425A1 (de) | 2001-10-01 | 2001-10-01 | Chromane |
| PCT/EP2002/010447 WO2003029250A1 (de) | 2001-10-01 | 2002-09-18 | Benzisothiazolyl-substituerte aminomethylcromane zur behandlung von erkrankungen des zentralen nervensystems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005507901A JP2005507901A (ja) | 2005-03-24 |
| JP2005507901A5 true JP2005507901A5 (https=) | 2006-01-05 |
Family
ID=7700998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532498A Withdrawn JP2005507901A (ja) | 2001-10-01 | 2002-09-18 | クロマン類 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6919360B2 (https=) |
| EP (1) | EP1434777A1 (https=) |
| JP (1) | JP2005507901A (https=) |
| CA (1) | CA2462142A1 (https=) |
| DE (1) | DE10148425A1 (https=) |
| WO (1) | WO2003029250A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2199086B1 (es) | 2002-07-31 | 2005-06-01 | Cepa Schwarz Pharma Sl | Nuevos derivados de cicloalcanodionas, procedimiento para su preparacion y sus aplicaciones farmacologicas. |
| ES2238015B1 (es) * | 2004-01-30 | 2006-11-01 | Cepa Schwarz Pharma, S.L. | Derivados de cicloalcanodionas con actividad neuroprotectora. |
| EP1856126A2 (en) * | 2005-02-17 | 2007-11-21 | Wyeth a Corporation of the State of Delaware | Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3901814A1 (de) | 1988-07-28 | 1990-02-01 | Bayer Ag | Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga |
| DE19522088A1 (de) * | 1995-06-19 | 1997-01-02 | Bayer Ag | Benzisothiazolyl-substituierte Aminomethylchromane |
| DE19543476A1 (de) * | 1995-11-22 | 1997-05-28 | Troponwerke Gmbh & Co Kg | Verwendung von substituierten Aminomethyl-chromanen zur Behandlung von Schädel-Hirn-Trauma |
-
2001
- 2001-10-01 DE DE10148425A patent/DE10148425A1/de not_active Withdrawn
-
2002
- 2002-09-18 EP EP02767489A patent/EP1434777A1/de not_active Withdrawn
- 2002-09-18 JP JP2003532498A patent/JP2005507901A/ja not_active Withdrawn
- 2002-09-18 WO PCT/EP2002/010447 patent/WO2003029250A1/de not_active Ceased
- 2002-09-18 US US10/490,315 patent/US6919360B2/en not_active Expired - Fee Related
- 2002-09-18 CA CA002462142A patent/CA2462142A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI404721B (zh) | 胺基－雜環化合物 | |
| TWI500616B (zh) | 新穎之雙環吡啶酮 | |
| TW201326182A (zh) | 六氫哌喃並［３，４－ｄ］［１，３］噻□－２－胺化合物類 | |
| JP6643247B2 (ja) | ガンマセクレターゼモジュレーターとしてのクロメンおよび１，１ａ，２，７Ｂ−テトラヒドロシクロプロパ［Ｃ］クロメンピリドピラジンジオン | |
| US10676438B2 (en) | KCNQ2-5 channel activator | |
| ES2733502T3 (es) | Compuestos de imidazopiridazina | |
| CN105246887B (zh) | 香豆素衍生物以及用于治疗过度增生性疾病的方法 | |
| TW201300384A (zh) | 新穎的雙環吡啶酮類 | |
| TW201105675A (en) | Compounds and compositions for the treatment of parasitic diseases | |
| HU229074B1 (en) | Tricyclic benzodiazepines as vasopressin receptor antagonists | |
| US10738063B2 (en) | 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
| WO2018019222A1 (zh) | 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途 | |
| ES2742078T3 (es) | Piridonas bicíclicas novedosas como moduladores de gamma-secretasa | |
| KR20220133227A (ko) | 알파-1 항트립신 결핍증의 치료 방법 | |
| JP6628805B2 (ja) | 新規シクロプロパベンゾフラニルピリドピラジンジオン | |
| US11267824B2 (en) | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase | |
| JP2005507901A5 (https=) | ||
| JP6230626B2 (ja) | ベンゾチアゾロン化合物を含む製剤 | |
| EP4229055B1 (en) | Compounds and compositions for the treatment of cryptosporidiosis | |
| KR102640385B1 (ko) | 고혈압 및/또는 폐 섬유증 치료용 조성물 | |
| JP2025517627A (ja) | 神経変性障害の治療のためのスルホンアミド化合物及びその薬学的組成物 | |
| JP2005507901A (ja) | クロマン類 | |
| BR112022019057B1 (pt) | Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune, seus usos, composição e combinação farmacêuticas, e kit | |
| TW200817321A (en) | Anthracene derivatives and their use for treating benign and malignant tumour disorders | |
| HK1262295B (zh) | 6 ,7-二氢-5H-吡唑并[5 ,1-b][1 ,3]恶嗪-2-甲酰胺化合物 |